Trial Profile

PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atuliflapon (Primary)
Indications Acute coronary syndromes; Myocardial infarction
Focus Therapeutic Use
Acronyms PASSIVATE

Most Recent Events

27 Apr 2025 Status changed from recruiting to discontinued. (The study was terminated early on 14th September 2023 by the main funding company because of financial futility. We were able to enroll 243 of the initial planned 360 participants and randomised 209 participants of the intial planned 286.)
13 Dec 2022 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.
13 Dec 2022 Planned primary completion date changed from 30 Apr 2023 to 31 Mar 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com